Latest Articles

Publication Date
An Immunomodulating Peptide With Potential to Counteract Endometriosis.

Endometriosis is underpinned by dysfunctional immune responses resulting in failure to clear ectopic endometrial lesions from the peritoneal cavity. The pelvic milieu comprising immature dendritic cells, dysfunctional cytotoxic lymphocytes, and …

Published: April 1, 2026, midnight
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - BioSpace

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis BioSpace

Published: March 23, 2026, 12:47 p.m.
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - PR Newswire

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis PR Newswire

Published: March 23, 2026, 11:30 a.m.
Detecting the body's reproductive hormonal brake against tissue overgrowth: Micrin/SgII-70.

A new humoral factor has been detected, within a project aiming to disclose the body's reproductive hormonal brake against tissue overgrowth, micrin ('my-crin'). Factor purification involved fractionation of ovine and …

Published: March 2, 2026, midnight
Engineering Anti-MMP-9 Peptide-Modified Nanoparticles for Precision MRI Diagnosis of Endometriosis.

Endometriosis diagnosis is often limited by the resolution of conventional imaging techniques (ultrasound/non-targeted MRI) as well as the invasiveness and recurrence risks associated with laparoscopy. To overcome these challenges, we …

Published: Feb. 27, 2026, midnight
Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia - 2 Minute Medicine

Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia 2 Minute Medicine

Published: Feb. 17, 2026, 12:15 a.m.
Atypical gelation of Elagolix sodium in aqueous media: Mechanistic insights and Inhibition via coamorphization.

Elagolix sodium (ELS), a non-peptide oral gonadotropin-releasing hormone receptor (GnRH) antagonist approved for the treatment of endometriosis-associated pain, displays atypical gelation in aqueous environments along with challenging physical properties such …

Published: Feb. 12, 2026, midnight
The Hidden Link Between Endometriosis and Obesity: A State-of-the-Art Review.

Endometriosis remains an under-researched disease with a wide range of symptoms. Endometriosis reduces a woman's quality of life and professional productivity, yet its exact causes, risk factors, and treatment have …

Published: Feb. 3, 2026, midnight
Influence of Oxidative Stress-Mediated Inflammation on the Pathogenesis of Reproductive Disorders: Exploring the Benefits of Carnosine for Prevention and Treatment of Endometriosis.

Endometriosis is a chronic pathological condition characterized by the growth of endometrial-like tissue outside the uterine cavity and is frequently associated with severe pain, persistent inflammation, and fibrosis within the …

Published: Jan. 30, 2026, midnight
Copper-Targeted Therapy in Experimental Endometriosis: Effects of Ammonium Tetrathiomolybdate on Markers of the Interconnected Processes of Inflammation, Innervation, and Fibrogenesis.

Endometriosis (EDT) is a chronic, estrogen-dependent disease characterized by inflammation, fibrosis, pelvic pain, and infertility. Current therapies show limited long-term efficacy and adverse effects, underscoring the need for novel therapeutic …

Published: Jan. 22, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!